JP2005508313A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005508313A5 JP2005508313A5 JP2003523241A JP2003523241A JP2005508313A5 JP 2005508313 A5 JP2005508313 A5 JP 2005508313A5 JP 2003523241 A JP2003523241 A JP 2003523241A JP 2003523241 A JP2003523241 A JP 2003523241A JP 2005508313 A5 JP2005508313 A5 JP 2005508313A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- phenyl
- carboxamide
- dihydro
- naphthyridin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 58
- 150000003839 salts Chemical class 0.000 claims 33
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 30
- 125000001424 substituent group Chemical group 0.000 claims 27
- 150000001875 compounds Chemical class 0.000 claims 24
- -1 phenylethynyl Chemical group 0.000 claims 13
- 150000002367 halogens Chemical group 0.000 claims 11
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical group CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 7
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- UFCOHPJEZNHBRJ-UHFFFAOYSA-N 4-oxo-3h-1,8-naphthyridine-3-carboxamide Chemical compound C1=CC=C2C(=O)C(C(=O)N)C=NC2=N1 UFCOHPJEZNHBRJ-UHFFFAOYSA-N 0.000 claims 3
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 claims 3
- 206010040070 Septic Shock Diseases 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 150000003857 carboxamides Chemical class 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 3
- 125000000335 thiazolyl group Chemical group 0.000 claims 3
- 125000001544 thienyl group Chemical group 0.000 claims 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 125000001041 indolyl group Chemical group 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- JQKSFYBCJSWDGS-UHFFFAOYSA-N n-cyclopropyl-4-oxo-1-[3-(2-pyridin-3-ylethynyl)phenyl]-1,8-naphthyridine-3-carboxamide Chemical compound C=1N(C=2C=C(C=CC=2)C#CC=2C=NC=CC=2)C2=NC=CC=C2C(=O)C=1C(=O)NC1CC1 JQKSFYBCJSWDGS-UHFFFAOYSA-N 0.000 claims 2
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 2
- 125000002971 oxazolyl group Chemical group 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 125000005494 pyridonyl group Chemical group 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- 230000036303 septic shock Effects 0.000 claims 2
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 2
- SFKQVNGDZONQSK-UHFFFAOYSA-N 1-(3-ethynylphenyl)-4-oxo-n-propan-2-yl-1,8-naphthyridine-3-carboxamide Chemical compound C12=NC=CC=C2C(=O)C(C(=O)NC(C)C)=CN1C1=CC=CC(C#C)=C1 SFKQVNGDZONQSK-UHFFFAOYSA-N 0.000 claims 1
- OJHOCHSVVQTTFZ-UHFFFAOYSA-N 1-[3-(3-hydroxy-3-phenylbut-1-ynyl)phenyl]-4-oxo-n-propan-2-yl-1,8-naphthyridine-3-carboxamide Chemical compound C12=NC=CC=C2C(=O)C(C(=O)NC(C)C)=CN1C(C=1)=CC=CC=1C#CC(C)(O)C1=CC=CC=C1 OJHOCHSVVQTTFZ-UHFFFAOYSA-N 0.000 claims 1
- MSYGAHOHLUJIKV-UHFFFAOYSA-N 3,5-dimethyl-1-(3-nitrophenyl)-1h-pyrazole-4-carboxylic acid ethyl ester Chemical compound CC1=C(C(=O)OCC)C(C)=NN1C1=CC=CC([N+]([O-])=O)=C1 MSYGAHOHLUJIKV-UHFFFAOYSA-N 0.000 claims 1
- ZMMAJVZOYAEFNK-UHFFFAOYSA-N 4-oxo-3h-1,8-naphthyridine-3-carboxylic acid Chemical compound C1=CC=C2C(=O)C(C(=O)O)C=NC2=N1 ZMMAJVZOYAEFNK-UHFFFAOYSA-N 0.000 claims 1
- CGVFWNBKVPBRRD-UHFFFAOYSA-N 4-oxo-n-propan-2-yl-1-[3-(2-pyridin-3-ylethynyl)phenyl]-1,8-naphthyridine-3-carboxamide Chemical compound C12=NC=CC=C2C(=O)C(C(=O)NC(C)C)=CN1C(C=1)=CC=CC=1C#CC1=CC=CN=C1 CGVFWNBKVPBRRD-UHFFFAOYSA-N 0.000 claims 1
- HLLJHFKTJJMYFK-UHFFFAOYSA-N 4-oxo-n-propan-2-yl-1-[3-(2-pyridin-4-ylethynyl)phenyl]-1,8-naphthyridine-3-carboxamide Chemical compound C12=NC=CC=C2C(=O)C(C(=O)NC(C)C)=CN1C(C=1)=CC=CC=1C#CC1=CC=NC=C1 HLLJHFKTJJMYFK-UHFFFAOYSA-N 0.000 claims 1
- WTIPGXDLKICFLA-UHFFFAOYSA-N 4-oxo-n-propan-2-yl-1-[3-(2-quinolin-3-ylethynyl)phenyl]-1,8-naphthyridine-3-carboxamide Chemical compound C12=NC=CC=C2C(=O)C(C(=O)NC(C)C)=CN1C1=CC=CC(C#CC=2C=C3C=CC=CC3=NC=2)=C1 WTIPGXDLKICFLA-UHFFFAOYSA-N 0.000 claims 1
- 208000004998 Abdominal Pain Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 206010051113 Arterial restenosis Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 102100039705 Beta-2 adrenergic receptor Human genes 0.000 claims 1
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- 208000002881 Colic Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 1
- 206010011224 Cough Diseases 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 208000020401 Depressive disease Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 241000283073 Equus caballus Species 0.000 claims 1
- 241000233866 Fungi Species 0.000 claims 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- 206010019196 Head injury Diseases 0.000 claims 1
- 208000032571 Infant acute respiratory distress syndrome Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010069698 Langerhans' cell histiocytosis Diseases 0.000 claims 1
- 229940126083 M3 antagonist Drugs 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 208000007201 Myocardial reperfusion injury Diseases 0.000 claims 1
- 206010028974 Neonatal respiratory distress syndrome Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000007920 Neurogenic Inflammation Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 claims 1
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 239000000048 adrenergic agonist Substances 0.000 claims 1
- 229940126157 adrenergic receptor agonist Drugs 0.000 claims 1
- 125000005037 alkyl phenyl group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 208000002205 allergic conjunctivitis Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000024998 atopic conjunctivitis Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229940111134 coxibs Drugs 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 201000003104 endogenous depression Diseases 0.000 claims 1
- 208000003401 eosinophilic granuloma Diseases 0.000 claims 1
- 239000000938 histamine H1 antagonist Substances 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000009545 invasion Effects 0.000 claims 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 claims 1
- 150000002617 leukotrienes Chemical class 0.000 claims 1
- 208000024714 major depressive disease Diseases 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 206010027175 memory impairment Diseases 0.000 claims 1
- 201000002652 newborn respiratory distress syndrome Diseases 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31609301P | 2001-08-29 | 2001-08-29 | |
| PCT/CA2002/001324 WO2003018579A1 (en) | 2001-08-29 | 2002-08-27 | Alkyne-aryl phosphodiesterase-4 inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005508313A JP2005508313A (ja) | 2005-03-31 |
| JP2005508313A5 true JP2005508313A5 (OSRAM) | 2005-12-22 |
| JP4157035B2 JP4157035B2 (ja) | 2008-09-24 |
Family
ID=23227432
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003523241A Expired - Fee Related JP4157035B2 (ja) | 2001-08-29 | 2002-08-27 | アルキン−アリールホスホジエステラーゼ−４阻害薬 |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US6743802B2 (OSRAM) |
| EP (2) | EP1436290B8 (OSRAM) |
| JP (1) | JP4157035B2 (OSRAM) |
| KR (1) | KR100928849B1 (OSRAM) |
| CN (1) | CN100338061C (OSRAM) |
| AR (1) | AR036365A1 (OSRAM) |
| AU (1) | AU2002322940B2 (OSRAM) |
| BR (1) | BR0212042A (OSRAM) |
| CA (1) | CA2456817C (OSRAM) |
| DO (1) | DOP2002000456A (OSRAM) |
| EA (1) | EA006800B1 (OSRAM) |
| EC (1) | ECSP044992A (OSRAM) |
| GE (1) | GEP20063805B (OSRAM) |
| HK (1) | HK1080073B (OSRAM) |
| HR (1) | HRP20040151A2 (OSRAM) |
| HU (1) | HUP0401729A3 (OSRAM) |
| IL (1) | IL160213A0 (OSRAM) |
| IS (1) | IS7138A (OSRAM) |
| JO (1) | JO2311B1 (OSRAM) |
| MX (1) | MXPA04001889A (OSRAM) |
| NO (1) | NO330521B1 (OSRAM) |
| NZ (1) | NZ530931A (OSRAM) |
| PE (1) | PE20030416A1 (OSRAM) |
| PL (1) | PL367716A1 (OSRAM) |
| RS (1) | RS17004A (OSRAM) |
| UA (1) | UA75957C2 (OSRAM) |
| WO (1) | WO2003018579A1 (OSRAM) |
| ZA (1) | ZA200400952B (OSRAM) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO2311B1 (en) * | 2001-08-29 | 2005-09-12 | ميرك فروست كندا ليمتد | Alkyl inhibitors Ariel phosphodiesterase-4 |
| DE10250708A1 (de) * | 2002-10-31 | 2004-05-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel |
| US7452911B2 (en) | 2002-10-31 | 2008-11-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds |
| US7351719B2 (en) | 2002-10-31 | 2008-04-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds |
| AU2003291418A1 (en) * | 2002-11-15 | 2004-06-15 | Merck And Co., Inc. | Use of pde4 inhibitors as adjunct therapy for psychiatric disorders |
| AR042194A1 (es) * | 2002-11-22 | 2005-06-15 | Merck & Co Inc | Metodo para preparar inhibidores de fosfodiesterasa - 4 |
| WO2004047836A1 (en) * | 2002-11-22 | 2004-06-10 | Merck Frosst Canada & Co. | Use of phosphodiesterase-4 inhibitors as enhancers of cognition |
| GB0307863D0 (en) * | 2003-04-04 | 2003-05-14 | Merck Sharp & Dohme | Therapeutic treatment |
| GB0322722D0 (en) * | 2003-09-27 | 2003-10-29 | Glaxo Group Ltd | Compounds |
| GB0322726D0 (en) * | 2003-09-27 | 2003-10-29 | Glaxo Group Ltd | Compounds |
| US7592373B2 (en) | 2003-12-23 | 2009-09-22 | Boehringer Ingelheim International Gmbh | Amide compounds with MCH antagonistic activity and medicaments comprising these compounds |
| DE102004017930A1 (de) * | 2004-04-14 | 2005-11-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel |
| US7524862B2 (en) | 2004-04-14 | 2009-04-28 | Boehringer Ingelheim International Gmbh | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds |
| DE102004017934A1 (de) | 2004-04-14 | 2005-11-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel |
| US20080119509A1 (en) * | 2004-04-26 | 2008-05-22 | Sophie-Dorothee Clas | Altenrative Forms Of The Phosphodeisterase -4 Inhibitor N-Cyclopropyl-1- -3{3-[(1-Oxidopyryidin-3-Yl) Phenyl]-4-Oxo-1,4-Dihydro-1,8-Naphthyridine-3-Carboxyamide |
| JP4264388B2 (ja) * | 2004-07-01 | 2009-05-13 | 富士通株式会社 | 半導体チップの接合方法および接合装置 |
| WO2006004191A1 (en) * | 2004-07-05 | 2006-01-12 | Astellas Pharma Inc. | Pyrrolopyridazine derivatives which inhibit pde iv and tnf alfa |
| US7687490B2 (en) * | 2005-04-12 | 2010-03-30 | Meiji Seika Kaisha, Ltd. | 2-thioethenyl substituted carbapenem derivatives |
| JP2006016407A (ja) * | 2005-06-15 | 2006-01-19 | Yamaha Motor Co Ltd | ホスホジエステラーゼ阻害剤 |
| US7678363B2 (en) | 2005-08-26 | 2010-03-16 | Braincells Inc | Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs |
| EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
| JP2009509980A (ja) * | 2005-09-28 | 2009-03-12 | メルク フロスト カナダ リミテツド | 篩分けされたラクトースを含むエアゾール粉末製剤 |
| WO2007047978A2 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
| AU2006308889A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | GABA receptor mediated modulation of neurogenesis |
| US7388016B2 (en) | 2005-12-13 | 2008-06-17 | Wyeth | Dibenzonaphthyridine derivatives and methods of use thereof |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| CA2651813A1 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| WO2007134077A2 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
| CA2662491A1 (en) | 2006-09-08 | 2008-03-13 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| CA2676715A1 (en) | 2007-02-12 | 2008-08-21 | Merck & Co., Inc. | Piperazine derivatives for treatment of ad and related conditions |
| US20090182035A1 (en) * | 2007-04-11 | 2009-07-16 | Alcon Research, Ltd. | Use of a combination of olopatadine and cilomilast to treat non-infectious rhinitis and allergic conjunctivitis |
| US20080254029A1 (en) * | 2007-04-11 | 2008-10-16 | Alcon Research, Ltd. | Use of an Inhibitor of TNFa Plus an Antihistamine to Treat Allergic Rhinitis and Allergic Conjunctivitis |
| US20100190761A1 (en) | 2007-06-20 | 2010-07-29 | Anthony Ogawa | Diphenyl substituted alkanes |
| CA2701956A1 (en) * | 2007-10-25 | 2009-04-30 | Merck Frosst Canada Ltd. | Combination therapy |
| WO2009128057A2 (en) | 2008-04-18 | 2009-10-22 | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al | Psycho-pharmaceuticals |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| CA2773483A1 (en) * | 2009-10-01 | 2011-04-07 | Alcon Research, Ltd. | Olopatadine compositions and uses thereof |
| FR2952934B1 (fr) * | 2009-11-23 | 2012-06-22 | Sanofi Aventis | Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique |
| WO2011099305A1 (en) | 2010-02-12 | 2011-08-18 | Raqualia Pharma Inc. | 5-ht4 receptor agonists for the treatment of dementia |
| AU2012222869B2 (en) * | 2011-03-02 | 2015-08-13 | Bionomics Limited | Methods of treating a disease or condition of the central nervous system |
| CN103183675A (zh) * | 2011-12-27 | 2013-07-03 | 山东轩竹医药科技有限公司 | 磷酸二酯酶-4抑制剂 |
| CN102643268B (zh) * | 2011-12-30 | 2014-05-21 | 沈阳药科大学 | 喹啉类及噌啉类化合物及其应用 |
| WO2013106547A1 (en) | 2012-01-10 | 2013-07-18 | President And Fellows Of Harvard College | Beta-cell replication promoting compounds and methods of their use |
| CN103214478B (zh) * | 2012-01-19 | 2015-07-15 | 山东轩竹医药科技有限公司 | 吡啶并氧代哒嗪衍生物 |
| BR112015019276A2 (pt) | 2013-02-19 | 2017-07-18 | Pfizer | compostos de azabenzimidazol como inibidores de isoenzimas de pde4 para o tratamento de distúrbios do snc e outros distúrbios |
| US10131669B2 (en) | 2014-07-24 | 2018-11-20 | Pfizer Inc. | Pyrazolopyrimidine compounds |
| EA031201B1 (ru) | 2014-08-06 | 2018-11-30 | Пфайзер Инк. | Соединения имидазопиридазина |
| JP2022515838A (ja) | 2018-12-28 | 2022-02-22 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | アラキドン酸１５－リポキシゲナーゼ（ａｌｏｘ１５）阻害剤による呼吸器障害の治療 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9212673D0 (en) | 1992-06-15 | 1992-07-29 | Celltech Ltd | Chemical compounds |
| GB9212693D0 (en) | 1992-06-15 | 1992-07-29 | Celltech Ltd | Chemical compounds |
| ES2092729T3 (es) | 1992-07-01 | 1996-12-01 | Hoechst Ag | Benzoilguanidinas 3,4,5-sustituidas, procedimiento para su preparacion, su empleo como medicamento o agente de diagnostico, asi como medicamento que las contiene. |
| GB9222253D0 (en) | 1992-10-23 | 1992-12-09 | Celltech Ltd | Chemical compounds |
| US5622977A (en) | 1992-12-23 | 1997-04-22 | Celltech Therapeutics Limited | Tri-substituted (aryl or heteroaryl) derivatives and pharmaceutical compositions containing the same |
| GB9226830D0 (en) | 1992-12-23 | 1993-02-17 | Celltech Ltd | Chemical compounds |
| DE4306152A1 (de) | 1993-02-27 | 1994-09-01 | Hoechst Ag | Positiv arbeitendes strahlungsempfindliches Gemisch und damit hergestelltes Aufzeichnungsmaterial |
| GB9304920D0 (en) | 1993-03-10 | 1993-04-28 | Celltech Ltd | Chemical compounds |
| GB9304919D0 (en) | 1993-03-10 | 1993-04-28 | Celltech Ltd | Chemical compounds |
| US5455252A (en) | 1993-03-31 | 1995-10-03 | Syntex (U.S.A.) Inc. | Optionally substituted 6,8-quinolines |
| DE4318756A1 (de) | 1993-06-05 | 1994-12-08 | Hoechst Ag | Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| GB9326173D0 (en) | 1993-12-22 | 1994-02-23 | Celltech Ltd | Chemical compounds and process |
| EP0738268B1 (en) | 1993-12-22 | 2004-03-03 | Celltech R&D Limited | Trisubstituted phenyl derivatives, processes for their preparation and their use as phosphodiesterase (type iv) inhibitors |
| GB9326699D0 (en) | 1993-12-22 | 1994-03-02 | Celltech Ltd | Chemical compounds |
| US6245774B1 (en) | 1994-06-21 | 2001-06-12 | Celltech Therapeutics Limited | Tri-substituted phenyl or pyridine derivatives |
| US5786354A (en) | 1994-06-21 | 1998-07-28 | Celltech Therapeutics, Limited | Tri-substituted phenyl derivatives and processes for their preparation |
| GB9412571D0 (en) | 1994-06-22 | 1994-08-10 | Celltech Ltd | Chemical compounds |
| GB9412573D0 (en) | 1994-06-22 | 1994-08-10 | Celltech Ltd | Chemical compounds |
| GB9412672D0 (en) | 1994-06-23 | 1994-08-10 | Celltech Ltd | Chemical compounds |
| EP0765867A1 (de) | 1995-09-27 | 1997-04-02 | Hoechst Aktiengesellschaft | Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Antiarrhytmika oder Diagnostikum sowie sie enthaltendes Medikament |
| GB9526243D0 (en) | 1995-12-21 | 1996-02-21 | Celltech Therapeutics Ltd | Chemical compounds |
| GB9526245D0 (en) | 1995-12-21 | 1996-02-21 | Celltech Therapeutics Ltd | Chemical compounds |
| GB9526246D0 (en) | 1995-12-21 | 1996-02-21 | Celltech Therapeutics Ltd | Chemical compounds |
| DE19622370A1 (de) | 1996-06-04 | 1997-12-11 | Hoechst Ag | Ortho-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| GB9625184D0 (en) | 1996-12-04 | 1997-01-22 | Celltech Therapeutics Ltd | Chemical compounds |
| EP0944582B1 (de) | 1996-12-11 | 2003-07-02 | Abbott GmbH & Co. KG | Ketobenzamide als calpain-inhibitoren |
| CA2268190A1 (en) | 1997-08-06 | 1999-02-18 | Suntory Limited | 1-aryl-1,8-naphthylidin-4-one derivative as type iv phosphodiesterase inhibitor |
| WO1999009504A1 (en) | 1997-08-20 | 1999-02-25 | First Data Corporation | Interactive tax payment system |
| US6331548B1 (en) * | 1998-01-29 | 2001-12-18 | Suntory Limited | 1-cycloalkyl-1,8-naphthyridin-4-one derivative as type IV phosphodiesterase inhibitor |
| ID27843A (id) * | 1998-08-11 | 2001-04-26 | Pfizer Prod Inc | Substitusi 1, 8-naftiridin-4(ih)-on sebagai penghambat fosfodiesterase 4 |
| JO2311B1 (en) * | 2001-08-29 | 2005-09-12 | ميرك فروست كندا ليمتد | Alkyl inhibitors Ariel phosphodiesterase-4 |
| IS7839A (is) * | 2002-11-22 | 2004-05-23 | Merck Frosst Canada Ltd. | 4-oxó-1-(3-setið fenýl-1,4-díhýdró-1,8-naftýridín-3-karboxamíð fosfódíesterasa-4 hindrar |
-
2002
- 2002-08-22 JO JO200289A patent/JO2311B1/en active
- 2002-08-23 US US10/226,980 patent/US6743802B2/en not_active Expired - Lifetime
- 2002-08-26 PE PE2002000819A patent/PE20030416A1/es not_active Application Discontinuation
- 2002-08-27 HR HR20040151A patent/HRP20040151A2/hr not_active Application Discontinuation
- 2002-08-27 AR ARP020103210A patent/AR036365A1/es not_active Application Discontinuation
- 2002-08-27 US US10/487,047 patent/US20050070569A1/en not_active Abandoned
- 2002-08-27 CN CNB028213270A patent/CN100338061C/zh not_active Expired - Fee Related
- 2002-08-27 WO PCT/CA2002/001324 patent/WO2003018579A1/en not_active Ceased
- 2002-08-27 EP EP02754079.8A patent/EP1436290B8/en not_active Expired - Lifetime
- 2002-08-27 EA EA200400361A patent/EA006800B1/ru not_active IP Right Cessation
- 2002-08-27 GE GE5495A patent/GEP20063805B/en unknown
- 2002-08-27 IL IL16021302A patent/IL160213A0/xx unknown
- 2002-08-27 PL PL02367716A patent/PL367716A1/xx not_active Application Discontinuation
- 2002-08-27 RS YUP-170/04A patent/RS17004A/sr unknown
- 2002-08-27 KR KR1020047002912A patent/KR100928849B1/ko not_active Expired - Fee Related
- 2002-08-27 HU HU0401729A patent/HUP0401729A3/hu unknown
- 2002-08-27 UA UA2004032266A patent/UA75957C2/uk unknown
- 2002-08-27 JP JP2003523241A patent/JP4157035B2/ja not_active Expired - Fee Related
- 2002-08-27 CA CA2456817A patent/CA2456817C/en not_active Expired - Fee Related
- 2002-08-27 MX MXPA04001889A patent/MXPA04001889A/es active IP Right Grant
- 2002-08-27 EP EP10191086A patent/EP2305677A1/en not_active Withdrawn
- 2002-08-27 AU AU2002322940A patent/AU2002322940B2/en not_active Ceased
- 2002-08-27 NZ NZ530931A patent/NZ530931A/en not_active IP Right Cessation
- 2002-08-27 BR BR0212042-9A patent/BR0212042A/pt not_active Application Discontinuation
- 2002-08-27 HK HK06100008.4A patent/HK1080073B/zh not_active IP Right Cessation
- 2002-08-29 DO DO2002000456A patent/DOP2002000456A/es unknown
-
2004
- 2004-01-30 IS IS7138A patent/IS7138A/is unknown
- 2004-02-05 ZA ZA200400952A patent/ZA200400952B/en unknown
- 2004-02-27 EC EC2004004992A patent/ECSP044992A/es unknown
- 2004-03-26 NO NO20041293A patent/NO330521B1/no not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005508313A5 (OSRAM) | ||
| CA2456817A1 (en) | Alkyne-aryl-naphthyridin-4 (1h)-one derivatives as type iv phosphodiesterase inhibitor | |
| AU722472B2 (en) | Quinoline carboxamides as TNF inhibitors and as PDE-IV inhibitors | |
| US6784192B2 (en) | Piperidine compound and pharmaceutical composition thereof | |
| US9108963B2 (en) | Pyrazolopyridine, pyrazolopyrazine, pyrazolopyrimidine, pyrazolothiophene and pyrazolothiazole compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | |
| TWI579284B (zh) | 咪唑并吡咯啶酮化合物 | |
| RU2345070C2 (ru) | Производные аминоиндазолов в качестве лекарственных средств, способ их получения и содержащие их фармацевтические композиции | |
| AU732863B2 (en) | Indole derivatives having combined 5HT1A, 5HT1B and 5HT1D receptor antagonist activity | |
| US20050209213A1 (en) | Quinoline compound | |
| JP2006502112A5 (OSRAM) | ||
| JP2007500177A5 (OSRAM) | ||
| CA2858681A1 (en) | Metalloenzyme inhibitor compounds | |
| JP2012510989A5 (OSRAM) | ||
| JP2005528325A5 (OSRAM) | ||
| CA2447765A1 (en) | 1-biaryl-1,8-napthyridin-4-one phosphodiesterase-4 inhibitors | |
| EA022815B1 (ru) | Антагонист рецептора cgrp | |
| CN110156785B (zh) | 吲唑类化合物及其制备方法和应用 | |
| US20020094987A1 (en) | Bicyclic aryl carboxamides and their therapeutic use | |
| JP3782011B2 (ja) | 置換８−アリールキノリン系ホスホジエステラーゼ−４阻害薬 | |
| US11319322B2 (en) | Substituted aryl ether compound, preparation method thereof, pharmaceutical composition and use thereof | |
| US9096531B2 (en) | Fused imidazole derivative | |
| TW201014852A (en) | Indolizine inhibitors of leukotriene production | |
| JP2020502252A5 (OSRAM) | ||
| JP2020500192A5 (OSRAM) | ||
| AU2001268075A1 (en) | 1-aryl-4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents |